Key Developments: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

32.73USD
28 Aug 2015
Change (% chg)

-- (--)
Prev Close
$32.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
625,058
52-wk High
$45.45
52-wk Low
$27.92

Search Stocks

Latest Key Developments (Source: Significant Developments)

Acorda Therapeutics Inc reiterates FY 2014 AMPYRA net revenue guidance
Thursday, 31 Jul 2014 06:00am EDT 

Acorda Therapeutics Inc:Reiterates FY 2014 guidance for AMPYRA net revenue of $328 mln -$335 mln.  Full Article

Acorda Therapeutics announces notification of ANDA filing for AMPYRA
Thursday, 26 Jun 2014 06:00am EDT 

Acorda Therapeutics Inc:Submits an Abbreviated New Drug Application (ANDA) to U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of AMPYRA(reg)(dalfampridine) Extended Release Tablets, 10 mg.Law firm of Kaye Scholer is advising Acorda on the ANDA filing.  Full Article

Acorda Therapeutics Inc prices $300 mln of convertible senior notes
Wednesday, 18 Jun 2014 06:00am EDT 

Acorda Therapeutics Inc:Prices public offering of $300 million principal amount of convertible senior notes due 2021.Notes will bear interest at annual rate of 1.75 pct and will mature on June 15, 2021, unless earlier converted, purchased or redeemed.Acorda granted underwriter an option to purchase up to additional $45 mln principal amount of Notes to cover over-allotments, if any.Intends to use net proceeds for general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products and technologies.J.P. Morgan Securities LLC is acting as sole book-running manager for the Notes offering.  Full Article

Acorda Therapeutics announces public offering of convertible senior notes due 2021
Monday, 16 Jun 2014 04:11pm EDT 

Acorda Therapeutics Inc:Says intention to offer $300 mln principal amount of convertible senior notes due 2021.Intends to grant the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any.Intends to use the net proceeds from this offering for general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products and technologies.J.P. Morgan Securities LLC is acting as the sole book-running manager for the Notes offering.  Full Article

Acorda Therapeutics Inc reiterates FY 2014 AMPYRA net revenue guidance
Tuesday, 6 May 2014 06:00am EDT 

Acorda Therapeutics Inc:Reiterates FY 2014 guidance for AMPYRA net revenue of $328-$335 mln.  Full Article

Acorda Therapeutics Inc Appoints Michael Rogers Chief Financial Officer; David Lawrence Named Chief of Business Operations
Monday, 7 Oct 2013 07:00am EDT 

Acorda Therapeutics Inc announced that Michael Rogers has joined the Company as Chief Financial Officer (CFO), effective October 7, 2013. He will assume responsibility for the Company`s Finance and Investor Relations departments. David Lawrence, M.B.A., who previously served as CFO, has been appointed Chief of Business Operations (CBO) and will be responsible for Technical Operations/Manufacturing, Project Management, Information Technology and Facilities Management.  Full Article

UPDATE 2-Hedge fund manager Kyle Bass loses challenges to pharma patents

NEW YORK, Aug 24 - Prominent hedge fund manager Kyle Bass's campaign to wipe out certain drug patents hit a roadblock on Monday when the U.S. Patent and Trademark Office declined to formally review two patents on Acorda Therapeutics Inc's flagship multiple sclerosis drug, Ampyra.

Search Stocks